Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Core MSCI Emerging Markets ETF (IEMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Core MSCI Emerging Markets ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while iShares Core MSCI Emerging Markets ETF trades at $80.05. Which is the better fit depends on your goals.
| ADPT | IEMG | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $22.37 | $86.00 |
52-Week Low | $10.24 | $59.90 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
IEMG trades at $82.00, up 2.71% with strong bullish technical signals from moving averages. The ETF has delivered exceptional performance, surging 35% over the past year according to Fool - Investing News (2026-07-06), driven by its 40% technology weighting and exposure to emerging market growth. Recent news highlights IEMG's valuation discount to US equities and its focus on AI through South Korean and Taiwanese semiconductor stocks.
The outlook remains positive given emerging market growth potential and AI exposure, though risks include elevated volatility at 37% and concentration in tech stocks. Analyst sentiment is mixed with some recommending profit-taking after the strong rally, while others emphasize the long-term growth opportunity in undervalued emerging markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →
